Contract Testing Business by PSS Shinjuku Laboratory
First written in FY2022. 3 of 9 entries say "Advanced", first in FY2023-Q1. Latest entry: FY2025.
0 other companies' latest entry also says "Other".
- FY2025Closure of the Shinjuku laboratory and decline in contract business revenueAnnual report
「PSS Shinjuku Laboratory (Shinjuku-ku, Tokyo) registered as a hygiene inspection laboratory (closed in March 2025)」
The PSS Shinjuku Laboratory was closed in March 2025, and revenue from the contract manufacturing and contract testing segment also declined to ¥185 million, down 11.7% year on year. - FY2024Continued decline in revenue from contract manufacturing and contract testingAnnual report
「For the fiscal year, revenue was ¥210 million, down 56.0% year on year.」
The PSS contract manufacturing and contract testing segment, including contract testing, recorded a decline in revenue from ¥477 million in FY2023 to ¥210 million. - FY2024-Q2Decline in revenue from contract manufacturing and contract testingAnnual report
「This segment comprises contract manufacturing conducted by NPS Co., Ltd., a manufacturing subsidiary, for external customers other than the Company, and contract testing at the PSS Shinjuku Laboratory. During the six-month period ended 30 September, revenue was ¥104 million, down 56.9% year on year.」
The contract manufacturing and contract testing segment, including contract testing at the PSS Shinjuku Laboratory, recorded revenue of ¥104 million, down 56.9% year on year. - FY2024-Q1Decline in revenue from the segment including contract testingAnnual report
「This segment comprises the contract manufacturing business conducted by エヌピーエス株式会社, a manufacturing subsidiary, for external customers other than the Company, as well as the Company’s contract testing business. In the cumulative first quarter, revenue was ¥45 million, down 48.9% year on year.」
The PSS contract manufacturing and contract testing segment, including contract testing, recorded revenue of ¥45 million, down 48.9% year on year. - FY2023MaterialisedAnnual report
「Because impairment indicators were identified for fixed assets related to several products scheduled for demonstration as custom-made machines and for the testing facility whose closure had been decided, their carrying amounts were reduced to recoverable amounts.」
The closure of testing facilities, including the PSS Shinjuku Laboratory, was decided, resulting in an impairment loss of ¥10.612 million. Meanwhile, revenue from the contract manufacturing and contract testing segment was ¥477 million, up 77.5% from the previous fiscal year. - FY2023-Q3AdvancedAnnual report
「This segment comprises external contract manufacturing conducted by エヌピーエス㈱, the subsidiary's manufacturing plant, for customers other than the company, and the company's contract testing business. In the cumulative third quarter, revenue was ¥386 million, up 89.4% year on year.」
The PSS contract manufacturing and contract testing segment, including contract testing, recorded revenue of ¥386 million, up 89.4% year on year, continuing the upward revenue trend through the previous quarter. - FY2023-Q2AdvancedAnnual report
「This segment comprises external contract manufacturing conducted by エヌピーエス㈱, the subsidiary's manufacturing plant, for customers other than the company, and contract testing at the PSS Shinjuku Laboratory. In the cumulative second quarter, revenue was ¥241 million, up 66.3% year on year.」
For the contract manufacturing and contract testing segment, including contract testing at the PSS Shinjuku Laboratory, revenue of ¥241 million was recorded, up 66.3% year on year. - FY2023-Q1AdvancedAnnual report
「This segment comprises external contract manufacturing conducted by エヌピーエス㈱, the subsidiary's manufacturing plant, for customers other than the company, and contract testing at the PSS Shinjuku Laboratory. In the cumulative first quarter, revenue was ¥88 million, up 48.9% year on year.」
For the contract manufacturing and contract testing segment, including contract testing launched at the PSS Shinjuku Laboratory in FY2022, revenue of ¥88 million was recorded, up 48.9% year on year. - FY2022First statedAnnual report
「The opening and registration of the Shinjuku Laboratory as a registered hygiene inspection laboratory led to the launch of the Tokyo PCR and Other Testing Free-of-Charge Program and a PCR testing program for workers at elderly care facilities and other sites in Matsudo, Chiba.」
The initiative to launch PCR testing programs in Tokyo and Matsudo, based on the opening and registration of the PSS Shinjuku Laboratory as a registered hygiene inspection laboratory, was identified independently for the first time as a strategic business initiative.